Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/82068
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDeane, A.-
dc.contributor.authorHorowitz, M.-
dc.date.issued2014-
dc.identifier.citationDiabetes Care, 2014; 37(2):e40-e41-
dc.identifier.issn0149-5992-
dc.identifier.issn1935-5548-
dc.identifier.urihttp://hdl.handle.net/2440/82068-
dc.description.statementofresponsibilityAdam M. Deane and Michael Horowitz-
dc.language.isoen-
dc.publisherAmerican Diabetes Association-
dc.rights© 2014 by the American Diabetes Association-
dc.source.urihttp://dx.doi.org/10.2337/dc13-1616-
dc.subjectHumans-
dc.subjectDiabetes Mellitus, Type 2-
dc.subjectReceptors, Glucagon-
dc.subjectIncretins-
dc.titleComment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?-
dc.typeJournal article-
dc.identifier.doi10.2337/dc13-1616-
pubs.publication-statusPublished-
dc.identifier.orcidDeane, A. [0000-0002-7620-5577]-
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]-
Appears in Collections:Anaesthesia and Intensive Care publications
Aurora harvest

Files in This Item:
File Description SizeFormat 
hdl_82068.pdfAccepted version120.43 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.